Literature DB >> 12379316

In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+ -ATPase activity in heart and liver of streptozotocin-diabetic rats: comparison with vitamin E.

Bilgehan Pekiner1, Nuray N Ulusu, Net Das-Evcimen, Meral Sahilli, Fugen Aktan, Milan Stefek, Svorad Stolc, Cimen Karasu.   

Abstract

Hyperglycemia leads to excess production of reactive oxygen species (ROS), lipid peroxidation and protein glycation that may impair cellular calcium homeostasis and results in calcium sequestration and dysfunction in diabetic tissues. Stobadine (ST) is a pyridoindole antioxidant has been postulated as a new cardio- and neuroprotectant. This study was undertaken to test the hypothesis that the treatment with ST inhibits calcium accumulation, reduces lipid peroxidation and protein glycation and can change Ca2+,Mg2+-ATPase activity in diabetic animals. The effects of vitamin E treatment were also evaluated and compared with the effects of combined treatment with ST. Diabetes was induced by streptozotocin (STZ, 55 mg/kg i.p.). Some of diabetic rats and their age-matched controls were treated orally with a low dose of ST (24.7 mg/kg/day), vitamin E (400-500 IU/kg/day) or ST plus vitamin E for 10 weeks. ST and vitamin E separately produced, in a similar degree, reduction in diabetes-induced hyperglycemia. Each antioxidant alone significantly lowered the levels of plasma lipid peroxidation, cardiac and hepatic protein glycation in diabetic rats but vitamin E treatment was found to be more effective than ST treatment alone. Diabetes-induced increase in plasma triacylglycerol levels was not significantly altered by vitamin E treatment but markedly reduced by ST alone. The treatment with each antioxidant completely prevented calcium accumulation in diabetic heart and liver. Microsomal Ca2+,Mg2+-ATPase activity significantly decreased in both tissues of untreated diabetic rats. ST alone significantly increased microsomal Ca2+,Mg2+-ATPase activity in the heart of normal rats. However, neither treatment with ST nor vitamin E alone, nor their combination did change cardiac Ca2+,Mg2+-ATPase activity in diabetic heart. In normal rats, neither antioxidant had a significant effect on hepatic Ca2+,Mg2+-ATPase activity. Hepatic Ca2+,Mg2+-ATPase activity of diabetic rats was not changed by single treatment with ST, while vitamin E alone completely prevented diabetes-induced inhibition in microsomal Ca2+,Mg2+-ATPase activity in liver. Combined treatment with ST and vitamin E provided more benefits in the reduction of hyperglycemia and lipid peroxidation in diabetic animals. This study describes potential mechanisms on cellular effects of ST in the presence of diabetes-induced hyperglycemia that may delay or inhibit the development of diabetic complications. The use of ST together with vitamin E can better control hyperglycemia-induced oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379316     DOI: 10.1016/s0925-4439(02)00141-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

1.  Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction.

Authors:  Tatiane M Murça; Patrícia L Moraes; Carolina A B Capuruço; Sérgio H S Santos; Marcos B Melo; Robson A S Santos; Vinayak Shenoy; Michael J Katovich; Mohan K Raizada; Anderson J Ferreira
Journal:  Regul Pept       Date:  2012-05-14

Review 2.  Carbonyl stress in aging process: role of vitamins and phytochemicals as redox regulators.

Authors:  Volkan Ergin; Reza Ebrahimi Hariry; Cimen Karasu
Journal:  Aging Dis       Date:  2013-10-01       Impact factor: 6.745

3.  Cytoprotective role of DL-alpha-lipoic acid in cyclophosphamide induced myocardial toxicity.

Authors:  Y Mythili; P T Sudharsan; P Varalakshmi
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

4.  Lupeol and its ester inhibit alteration of myocardial permeability in cyclophosphamide administered rats.

Authors:  Periyasamy Thandavan Sudharsan; Yenjerla Mythili; Elangovan Selvakumar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2006-09-29       Impact factor: 3.396

5.  Pentose phosphate pathway, glutathione-dependent enzymes and antioxidant defense during oxidative stress in diabetic rodent brain and peripheral organs: effects of stobadine and vitamin E.

Authors:  Nuray N Ulusu; Meral Sahilli; Aslihan Avci; Orhan Canbolat; Gülgün Ozansoy; Nuray Ari; Musa Bali; Milan Stefek; Svorad Stolc; Andrej Gajdosik; Cimen Karasu
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

6.  Role of nitric oxide, tetrahydrobiopterin and peroxynitrite in glucose toxicity-associated contractile dysfunction in ventricular myocytes.

Authors:  L B Esberg; J Ren
Journal:  Diabetologia       Date:  2003-07-29       Impact factor: 10.122

7.  Diabetic cardiomyopathy and reactive oxygen species (ROS) related parameters in male and female rats: A comparative study.

Authors:  Vidya Akhileshwar; Samir P Patel; Surendra S Katyare
Journal:  Indian J Clin Biochem       Date:  2007-03

8.  Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment.

Authors:  Cimen Karasu
Journal:  Open Cardiovasc Med J       Date:  2010-11-26

9.  Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose.

Authors:  Zubeyir Elmazoglu; Marta Soltesova Prnova; Abel Santamaria; Milan Stefek; Cimen Karasu
Journal:  Neurotox Res       Date:  2020-11-04       Impact factor: 3.911

Review 10.  Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications.

Authors:  Lucia Kovacikova; Marta Soltesova Prnova; Magdalena Majekova; Andrej Bohac; Cimen Karasu; Milan Stefek
Journal:  Molecules       Date:  2021-05-12       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.